1
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Jeffrey H Tidwell, Stephen D Prodnuk, Vincent P Liptak, December 28, 2010: US07858643 (6 worldwide citation)

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


2
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Agouron Pharmaceuticals, March 2, 2006: US20060046991-A1

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


3
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, October 18, 2012: US20120263706-A1

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


4
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Pfizer, December 23, 2010: US20100324061-A1

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


5
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Agouron Pharmaceuticals, June 15, 2006: US20060128724-A1

Compounds of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


6
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Agouron Pharmaceuticals, August 10, 2006: US20060178374-A1

Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


7
Robert Steven Kania, Steven Lee Bender, Allen J Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson Jr, Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Marie Tempczyk Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. Agouron Pharmaceuticals, March 18, 2003: US06534524 (85 worldwide citation)

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The inv ...


8
Siegfried Heinz Reich, Ted Michael Bleckman, Susan Elizabeth Kephart, William Henry Romines, Michael B Wallace: Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation. Agouron Pharmaceuticals, Bryan C Zielinski, Joseph F Reidy, Wendy Lei Hsu, April 29, 2003: US06555539 (60 worldwide citation)

Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation ...


9
Bruce A Dressman, James E Fritz, Marlys Hammond, William J Hornback, Stephen W Kaldor, Vincent J Kalish, John E Munroe, Siegfried H Reich, John H Tatlock, Timothy A Shepherd, Michael J Rodriguez: HIV protease inhibitors. Agouron Pharmaceuticals, Finnegan Henderson Farabow Garrett & Dunner, January 16, 1996: US05484926 (59 worldwide citation)

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral ...


10
Steven L Bender, Michael J Melnick: Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses. Agouron Pharmaceuticals, Finnegan Henderson Farabow Garrett & Dunner L, May 19, 1998: US05753653 (57 worldwide citation)

The invention relates to compounds of the formula I ##STR1## in which Q is a divalent radical having four ring atoms which together with C* and N form a six-membered ring, each of these four ring atoms being unsubstituted or substituted by a suitable substituent and at least one being a heteroatom s ...